Berenberg hikes AstraZeneca target price, eyes product launches

Alexander Bueso Sharecast | 20 Mar, 2017 12:52 - Updated: 12:52 | | |

astrazeneca

AstraZeneca

4,661.00

09:05 28/04/17
-0.79%
-37.00
  • 7,213.68
  • -0.32%-23.49
  • Max: 7,243.31
  • Min: 7,210.93
  • Volume: 0
  • MM 200 : n/a
09:05 28/04/17
  • 3,472.76
  • -0.23%-8.08
  • Max: 3,483.33
  • Min: 3,472.28
  • Volume: 0
  • MM 200 : n/a
09:05 28/04/17
  • 1,519.89
  • -0.16%-2.50
  • Max: 1,521.81
  • Min: 1,519.04
  • Volume: 0
  • MM 200 : n/a
09:05 28/04/17
  • 13,619.58
  • -0.68%-92.61
  • Max: 13,722.19
  • Min: 13,612.67
  • Volume: 0
  • MM 200 : n/a
09:05 28/04/17
  • 4,019.72
  • -0.28%-11.25
  • Max: 4,034.05
  • Min: 4,018.43
  • Volume: 0
  • MM 200 : n/a
09:05 28/04/17
  • 3,966.86
  • -0.26%-10.48
  • Max: 3,980.41
  • Min: 3,965.60
  • Volume: 0
  • MM 200 : n/a
09:05 28/04/17

Analysts at Berenberg pushed up their target price on AstraZeneca in anticipation of multiple blockbuster launches and lessened competitive headwinds from generics in 2017.

By year-end, the impact from its patent expiries should also have dropped out from the annual comparisons, the German broker said in a research note published on Monday but dated 17 March.

Analysts Alistair Campbell, Joseph Lockey and Laura Sutcliffe PhD bumped up their target from 4866p to 5670p and reiterated a 'Buy' recommendation.

Dominating the outlook for the company in the very short-term were its immuno-oncology (IO) drug, Durvalumab, and its first-line lung cancer drug trial, MYSTIC.

The latter marked an important milestone, the analysts said, with lung cancer potentially adding $2.5bn of sales; nevertheless, although it was not essential for the drugmaker's turnaround it had a reasonable chance of success, they said.

Should MYSTIC fail, Berenberg's discounted cash-flow models pointed to a share price value of 5158p.

"This does not offer much upside from current levels, but also implies that MYSTIC expectations are not aggressively high. If we assume MYSTIC success, and remove our risk weighting entirely, our DCF climbs to £59.19, giving 22% upside from current levels."

Astra's pipeline and current launches might add $10.0bn to the topline, with IO accounting for a quarter of that.

When risk-weighted, that pipeline would help the London-based frim grow sales at a yearly clip of 8% between 2017 and 2023.

The firm would also be able to rein in cost growth , helping margins to recover and driving EPS gains per annum of 28%, they said.

EBIT margins were seen recovering from 17.5% in 2017 top 20.7% in 2018 and 25.1% for 2019. In 2016 they clocked in at 29.2%.

More news

09:19 UK consumer confidence worsens again in April - GfK

UK consumer confidence worsened slightly in April due to worries about rising inflation and flat wages.

08:58 Ultra Electronics remains confident despite US funding delays

Ultra Electronics said the expected improvement in trading from the new US government continued to be delayed as Federal budgets were negotiated.

08:41 RBS swings into first quarterly profit since 2015

Royal Bank of Scotland broke into the black in the first quarter of 2017, the first quarterly profit since 2015 as income, costs and margins all improved.

09:01 UK house prices fall again in April, says Nationwide

UK house prices have fallen for the second month in a row, with annual growth slowing to a near four-year low.

00:11 US close: Wall Street closes in the green as earnings season peaks

Wall Street bounced back quickly but modestly on Thursday as the peak day of the earnings season was rather mixed, with investors still getting over their disappointment over White House tax cut plans the previous day.

27 Apr Lloyds Banking Group profit increases, on track to meet 2017 targets

Lloyds Banking Group’s first quarter profit increased with the part state-owned bank still on track to meet its 2017 targets.

27 Apr ECB policy decision - Analysts react

"In June we expect a change to a less dovish and more symmetric forward guidance that would open the door for depo rate hikes in 2018. In particular, we would expect modifications possibly to both the forward guidance on rates and on QE by removing the explicit reference in the statement to a scenario with lower rates and/or higher QE." - Philippe Gudin, Antonio Garcia Pascual, Barclays Research

27 Apr FX round-up: Sterling sails higher on UK retail data, ECB rate call

Sterling sailed higher on most key crosses Thursday as investors liked the currency after pleasing UK retail data, European Central Bank holding interest rates and last night's US tax-reform disappointment.

27 Apr Europe close: ECB pours cold water on expectations of policy shift

European stocks declined for the first time in seven days despite the European Central Bank sounding a more confident note on the single currency bloc's economy.

27 Apr Friday preview: UK economic growth seen slowing, RBS results under scrutiny

On Friday the Office for National Statistics will reveal its preliminary estimate for UK gross domestic product growth for the first quarter.